↓ Skip to main content

Cardiovascular Complications Associated With Novel Cancer Immunotherapies

Overview of attention for article published in Current Treatment Options in Cardiovascular Medicine, April 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#30 of 416)
  • High Attention Score compared to outputs of the same age (86th percentile)
  • High Attention Score compared to outputs of the same age and source (95th percentile)

Citations

dimensions_citation
78 Dimensions

Readers on

mendeley
72 Mendeley
Title
Cardiovascular Complications Associated With Novel Cancer Immunotherapies
Published in
Current Treatment Options in Cardiovascular Medicine, April 2017
DOI 10.1007/s11936-017-0532-8
Pubmed ID
Authors

Varun Jain, Jaspreet Bahia, Mahsa Mohebtash, Ana Barac

Abstract

Immune therapies represent a quantum leap in the fight against cancer. Recently approved immune checkpoint inhibitors that target receptors involved in immune escape of cancer cells (including cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), programmed cell death protein-1 (PD-1), and programmed cell death protein ligand-1 (PD-L1) are increasingly being used for therapeutic benefit in a number of cancers. The robust anti-cancer activity of these agents has been accompanied by the recognition of new adverse effects, often due to the over activation of immune system, that may limit their therapeutic benefit and adversely impact outcomes. Combination treatments in particular, such as approaches using two targeted immunotherapy agents, have higher risk of adverse effects. Our review focuses on the approved checkpoint inhibitor therapies and their potential for cardiovascular toxicity. While very few cases of autoimmune cardiotoxicity and myocarditis have been reported in clinical trials, severe, life-threatening episodes of heart failure and hemodynamic compromise associated with the use of immune checkpoint inhibitors have recently been reported in the literature. Early recognition, diagnosis, and management of autoimmune myocarditis represent an important clinical challenge with no current guidelines available for prevention, identification, and treatment of this serious condition. This area of cardio-oncology is evolving rapidly as more drugs in this class are being discovered and pending approval. There is a need for future studies focused on prospective identification of biomarkers and clinical standards for treatment and long-term follow-up of cardiovascular toxicity to successfully continue the treatment of cancer while preventing the adverse outcomes with novel immune therapies.

X Demographics

X Demographics

The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 72 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 1%
Unknown 71 99%

Demographic breakdown

Readers by professional status Count As %
Researcher 11 15%
Other 10 14%
Student > Doctoral Student 7 10%
Student > Bachelor 7 10%
Student > Ph. D. Student 5 7%
Other 17 24%
Unknown 15 21%
Readers by discipline Count As %
Medicine and Dentistry 35 49%
Biochemistry, Genetics and Molecular Biology 7 10%
Pharmacology, Toxicology and Pharmaceutical Science 4 6%
Nursing and Health Professions 1 1%
Unspecified 1 1%
Other 4 6%
Unknown 20 28%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 January 2018.
All research outputs
#1,970,183
of 22,963,381 outputs
Outputs from Current Treatment Options in Cardiovascular Medicine
#30
of 416 outputs
Outputs of similar age
#40,323
of 310,118 outputs
Outputs of similar age from Current Treatment Options in Cardiovascular Medicine
#1
of 21 outputs
Altmetric has tracked 22,963,381 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 416 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.7. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 310,118 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.